Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage immuno-oncology company, renowned for its innovation in next-generation cancer immunotherapies. Headquartered in Gaithersburg, MD, Sensei leverages its proprietary TMAb™ (Tumor Microenvironment Activated biologics) platform to develop cutting-edge therapeutics designed to harness the body's immune system against cancer. The company’s leading product candidates include SNS-101, SNS-102, SNS-103, and SNS-201, all of which are conditionally active antibodies targeting different immunosuppressive markers within the tumor microenvironment.
Sensei’s flagship candidate, SNS-101, is designed to block the VISTA (V-domain Ig suppressor of T cell activation) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 is currently undergoing a multi-center Phase 1/2 clinical trial, evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as both a monotherapy and in combination with Regeneron's PD-1 inhibitor, Libtayo® (cemiplimab), in patients with advanced solid tumors. Initial data are promising, showing SNS-101 to be well-tolerated and demonstrating clinical activity, particularly in tumor types typically resistant to PD-1 monotherapy.
Other promising candidates include SNS-102, targeting VSIG-4 (V-Set and Immunoglobulin Domain Containing 4), and SNS-103, targeting CD39 (ecto-nucleoside triphosphate diphosphohydrolase-1), as well as SNS-201, a conditionally active VISTAxCD28 bispecific antibody. The company has established key academic collaborations, including with Brown University, to bolster its research and development efforts.
Financially, Sensei maintains a strong balance sheet with cash reserves projected to fund operations into the second half of 2025. Recent financial updates show reduced R&D and G&A expenses due to strategic restructuring, leading to a narrower net loss. The company is focused on advancing its clinical trials, with expected milestones including initial combination safety and pharmacokinetic data for SNS-101 in early 2024, followed by topline monotherapy data later in the year.
For more information, visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
Sensei Biotherapeutics (NASDAQ: SNSE) announced promising preclinical data for its anti-VISTA product candidate, SNS-101. This monoclonal antibody selectively binds to the active form of VISTA in low pH tumor environments, enhancing immune response. Key findings include SNS-101's high affinity and selectivity (~600-fold) for low pH conditions and improved anti-tumor activity when combined with anti-PD-1 therapy. The company is actively pursuing IND-enabling studies and will present findings at the SITC 2021 meeting. A virtual symposium on VISTA's potential will occur on November 16.
SNS-101, a novel tumor-selective anti-VISTA antibody candidate, has been identified by Sensei Biotherapeutics, aimed at overcoming resistance to cancer therapies. Its preclinical data will be presented at the Society for Immunotherapy of Cancer’s annual meeting. As of September 30, 2021, the company reported $156.7 million in cash, ensuring its operational runway through the first half of 2024. R&D expenses increased to $6.4 million, while net loss widened to $9.7 million compared to $5.4 million in Q3 2020. Sensei is progressing with its TMAb platform and anticipates further updates on the ImmunoPhage platform.
Sensei Biotherapeutics (NASDAQ: SNSE) announced that CEO John Celebi will participate in a fireside chat at the Berenberg virtual U.S. CEO Conference on November 9, 2021, at 10:00 a.m. EST. The event will be accessible via a live audio webcast on the company’s website, with a replay available for 90 days afterward. Sensei focuses on developing next-generation immunotherapies for cancer, leveraging its unique TMAb™ and ImmunoPhage™ platforms, including the therapeutic candidate SNS-101 targeting immune checkpoint VISTA and the ImmunoPhage cocktail SNS-401-NG for Merkel Cell Carcinoma.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its presentation of preclinical data for its anti-VISTA candidate, SNS-101, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-14, 2021. The data will mark the first scientific presentation from Sensei's TMAb platform, which aims to enhance immune checkpoint therapies through tumor microenvironment selectivity. SNS-101 targets VISTA, a crucial immune checkpoint, to potentially boost anti-cancer immune responses while minimizing side effects.
Sensei Biotherapeutics (NASDAQ: SNSE) reported financial results for Q2 2021, highlighting significant developments in its SNS-VISTA program, which showed notable anti-tumor activity. The company aims to select a lead candidate and begin IND-enabling studies by year-end 2021. As of June 30, 2021, Sensei maintained a strong cash position of $162.5 million, expected to fund operations into 2024. However, the company experienced increased R&D expenses of $5.9 million and a net loss of $9.8 million, reflecting higher operational costs.
Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Kristian Humer as an independent director, effective July 30, 2021. Humer, who joins from Viridian Therapeutics, brings over 20 years of experience in life sciences investment banking. The company’s CEO, John Celebi, expressed confidence in Humer's expertise to guide the firm through its growth phase as a public company. Sensei Biotherapeutics is focused on developing next-generation cancer immunotherapies, leveraging innovative platforms such as ImmunoPhage and TMAb.
Sensei Biotherapeutics is shifting its focus towards developing next-generation phage product candidates, including SNS-401-NG and SNS-VISTA, while discontinuing the SNS-301 program due to suboptimal clinical findings. The decision was driven by an analysis that revealed insufficient T-cell activation. This strategic pivot extends the company's cash runway into the first half of 2024, supporting ongoing operations. Sensei plans to initiate IND-enabling studies for SNS-401-NG by late 2022 and share comprehensive SNS-301 data at a future scientific conference.
Sensei Biotherapeutics reported promising results from its Phase 1/2 trial of SNS-301, an investigational therapy for advanced squamous cell carcinoma of the head and neck. Data shows that SNS-301 combined with pembrolizumab demonstrated a favorable safety profile and a potential for durable tumor responses. Notably, one patient experienced a 71% tumor reduction lasting 11 months. The company expects to provide updated data, including frontline therapy results, by year-end, enhancing the understanding of its proprietary ImmunoPhage platform.
Sensei Biotherapeutics (NASDAQ: SNSE) reported strong progress in Q1 2021, highlighting advancements in its ImmunoPhage™ platform and the VISTA program. The company has commenced patient dosing in a Phase 1/2 study of SNS-301 for squamous cell carcinoma, with data accepted for presentation at ASCO 2021. Sensei ended the quarter with $169.4 million in cash, ensuring funding through at least mid-2023. The recent IPO raised $152.6 million, which will support ongoing and future research initiatives.
Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Dr. Maura Gillison and Dr. Richard Ulevitch to its Immuno-Oncology Advisory Board. Dr. Gillison, an expert in head and neck cancers, and Dr. Ulevitch, a leader in innate immunity, bring extensive knowledge to the company's strategic direction. Their insights aim to enhance the potential of the ImmunoPhage™ platform and foster collaboration among advisors to drive advancements in cancer treatment. This move is seen as a step towards bolstering Sensei's capabilities in developing innovative immunotherapies.
FAQ
What is the current stock price of Sensei Biotherapeutics (SNSE)?
What is the market cap of Sensei Biotherapeutics (SNSE)?
What is Sensei Biotherapeutics, Inc.?
What products is Sensei developing?
What is SNS-101?
What are the recent achievements of the company?
Where is Sensei Biotherapeutics headquartered?
What is the TMAb™ platform?
What financial status does Sensei Biotherapeutics have?
Who are Sensei's key collaborators?
What are the anticipated milestones for SNS-101?
Where can I find more information about Sensei Biotherapeutics?
